When do you consider tapering tocilizumab in patients with GCA in remission?
Answer from: at Academic Institution
This is a timely question and recent data sheds some light on this important topic. The risk of GCA relapse is approximately 50% (Mainbourg et al., PMID 30951256) in all comers. The GIACTA trial (Stone et al., PMID 28745999) utilized a one-year course of TCZ. A recent publication of the extensi...
Comments
at University of Kentucky I recently ran into a case of GCA that was NOT bas...
I recently ran into a case of GCA that was NOT bas...